查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
RNA治疗临床试验市场规模、份额、趋势分析报告：按模式、阶段、治疗领域、地区、细分趋势，2023-2030年
市场调查报告书
商品编码
1321424

RNA治疗临床试验市场规模、份额、趋势分析报告：按模式、阶段、治疗领域、地区、细分趋势，2023-2030年

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

RNA治疗临床试验市场增长和趋势

Grand View Research 的最新报告显示，到 2030 年，全球 RNA 治疗临床试验市场预计将达到 35 亿美元。

预计2023年至2030年该市场将以3.84%的年复合成长率增长。新兴市场的增长是由生物技术和製药公司的升级推动的，感染疾病和罕见疾病负担的增加、基于 RNA 的 COVID-19 疫苗成功率的提高、法规的批准和个体化药物的推动。需求正在推动市场增长。

此外，RNA疗法是一种很有前途的疾病治疗或预防方法，导致多项RNA临床试验的增加。此外，对不同类型RNA及其治疗各种人类疾病和病症的能力的长期研究工作带来了强劲的市场需求。此外，RNA 疗法（其中 RNA 本身充当药物或靶点）的潜在好处是针对罕见和难以治疗的疾病开发新药的创新方法。

在全球范围内，感染疾病和罕见病仍然是导致死亡的主要原因，生物技术和製药公司越来越关注开发新药。因此，基于RNA的治疗技术创新不断进步，对RNA治疗的临床试验产生了巨大的需求。此外，罕见疾病仍然是 RNA 疗法最具针对性的治疗领域。

此外，根据美国食品药物管理局(FDA) 的数据，截至 2022 年 12 月，超过 7,000 种罕见疾病影响了美国超过3000 万人；根据欧盟委员会的数据，截至2023 年2 月，超过30 种罕见疾病影响了美国超过3000 万人。美国有 100 万人受到罕见疾病的影响。全球有多达 3600 万人患有罕见疾病。欧盟有 6000 多种不同的罕见疾病。同样，加深对 RNA 功能及其在疾病预防中的作用的了解正在促进 RNA 的各种应用。

COVID-19 大流行严重影响了 RNA 治疗临床试验市场的增长。製药和生物技术公司突然关注疫苗开发和研发活动无疑扰乱了世界各地的 RNA 临床试验。然而，研究人员对基于 RNA 的 COVID-19 疫苗开发的兴趣日益浓厚，支持了市场的积极增长。此外，人们对将 RNA 用于其他感染疾病和肿瘤适应症也很感兴趣。这些要素正在推动市场增长。

此外，主要参与企业正在采取联盟、协议、联合研究和市场启动等战略，以扩大其全球影响力和产品系列。例如，2021 年 3 月，IQVIA 公司宣布与 Janssen Research & Development, LLC 合作开展 COVID-19 疫苗 3 期临床试验。该考试结合了虚拟监督、远端医疗技术和数字病人参与策略，以支持远程和现场考试。

RNA 治疗临床试验市场报告亮点

  • 信使RNA细分市场在2022年占据最大的销售份额，为35.7%，因为基因表现领域的研究人员数量不断增加，技术进步促进了该细分市场的增长。
  • II 期细分市场在 RNA 治疗临床试验市场占据主导地位，2022 年收入份额为 41.3%。 RNA 治疗的有效性和 RNA 临床试验的安全性预计将推动细分市场的增长。
  • 2022年，罕见病细分市场占据主导地位，占销售份额的21.8%。增长的主要要素是不同类型罕见疾病负担的增加。市场参与企业的研发支出也是市场增长的驱动力。
  • 2022年，北美地区的销售份额最大，为36.6%。成熟市场参与者的存在、罕见疾病负担的增加、RNA 研究活动的活性化以及临床试验数量的增加正在推动该地区的增长。
  • 此外，持续的技术创新和不断增加的临床研究和试验正在推动该地区的市场增长。例如，2022年12月，Moderna和默克提到了mRNA-4157/V940的2b期KEYNOTE-942/mRNA-4157-P201试验，这是一种与KEYTRUDA联合使用的个体化mRNA癌症疫苗。这是一种 mRNA 癌症疫苗，用于治疗 III/IV 期黑色素瘤患者。
  • 主导市场的一些主要企业包括 IQVIA、Laboratory Corporation of America Holdings、ICON Plc、Charles River Laboratories International, Inc.、PPD Inc.、Syneos Health、Medpace Holdings, Inc.、Novotech、PAREXEL International Corp.、Veristat、有限责任公司。

目录

第1章调查方法和范围

  • 资讯采购
  • 资讯或资料分析
  • 市场范围和细分定义
  • 市场模式

第2章执行摘要

第3章市场变量、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/辅助市场预测
  • 市场趋势及展望
  • 市场动态
  • 市场促进因素分析
  • 市场抑制因素分析
  • 营商环境分析
    • SWOT分析
    • 波特五力分析
  • COVID-19 影响分析

第4章模态业务分析

  • RNA治疗临床试验市场：模态变异分析
  • RNA干扰
  • 反义疗法
  • 信使核糖核酸
  • 寡核苷酸，非反义，非RNAi

第5章临床试验阶段业务分析

  • RNA治疗临床试验市场：临床试验阶段变异分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第6章治疗领域业务分析

  • RNA治疗临床试验市场：治疗领域波动分析
  • 罕见疾病
  • 抗感染疾病
  • 抗癌剂
  • 神经系统
  • 消化器官系统/代谢系统
  • 肌肉骨骼系统
  • 心血管、呼吸系统
  • 情怀
  • 其他的

第7章区域业务分析

  • 2022 年和 2030 年按地区分類的 RNA 治疗临床试验市场份额
  • 北美
    • 2018-2030年北美RNA治疗临床试验市场
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030年欧洲RNA疗法临床试验市场
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 亚太地区RNA治疗临床试验市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 泰国
  • 拉美
    • 拉丁美洲RNA治疗临床试验市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 2018-2030年中东和非洲RNA治疗临床试验市场
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第8章竞争形势

  • 公司分类
  • 战略规划
    • 併购
    • 合作
    • 新产品发布
  • 参与企业概况
    • IQVIA
    • ICON Plc
    • Laboratory Corporation of America Holdings
    • Charles River Laboratories International, Inc.
    • PAREXEL International Corp.
    • Syneos Health
    • Medpace Holdings, Inc.
    • PPD Inc.
    • Novotech
    • Veristat, LLC.
Product Code: GVR-4-68040-100-2

RNA Therapy Clinical Trials Market Growth & Trends

The global RNA therapy clinical trials market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 3.84% from 2023 to 2030. The growth of the market in emerging countries is due to escalating biotechnology and pharmaceutical companies, the increasing burden of infectious and rare diseases, the growing success rate of RNA-based COVID-19 vaccines, regulatory approval, and demand for personalized medicines drive the market growth.

Besides, RNA therapy acts as a promising therapeutic approach for the treatment or prevention of diseases leading to a rise in several RNA clinical trials. Additionally, long-term research activities on various types of RNAs, and the ability of RNA to treat various human diseases and disorders have led to strong demand for the market. Also, the potential benefit of RNA therapy wherein RNA itself serves as either a drug or a target provides acts as an innovative approach for developing new drugs for rare or difficult-to-treat diseases.

Globally, infectious diseases and rare diseases remain the leading cause of death, which has gained the increased attention of biotechnology and pharmaceutical companies to develop new drugs. This led to the rise in the innovation of RNA-based therapy creating immense requirements for RNA therapy clinical trials. Additionally, rare diseases remain the top targeted therapeutic area by RNA therapies.

Furthermore, according to the US Food & Drug Administration, in December 2022, over 7,000 rare diseases affected more than 30 million people in the U.S. whereas according to European Commission as of February 2023, up to 36 million European population live with a rare disease. There are 6000+ distinct rare diseases in the EU. Likewise, the increasing understanding of RNA functions and their roles in disease prevention has promoted various RNAs application.

The COVID-19 pandemic has greatly impacted the growth of the RNA therapy clinical trials market. The sudden focus of pharmaceutical and biotechnology companies on the development of the vaccine, research, and development activities had certainly disrupted the RNA clinical trials across the globe. However, the increasing interest of researchers to develop an RNA-based COVID-19 vaccine has supported the market with positive growth. Additionally, it has also sparked an interest in RNA use against other infectious diseases and oncology indications. These factors drive the growth of the market.

Furthermore, the key participants engage in strategies such as partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio. For instance, in March 2021, IQVIA Company announced the collaboration with Janssen Research & Development, LLC for Phase 3 COVID-19 vaccine clinical trials. The studies will support both remote and on-site studies through a mix of virtual oversight, telehealth technologies, and digital patient engagement strategies.

RNA Therapy Clinical Trail Market Report Highlights

  • The messenger RNA segment held the largest revenue share of 35.7% in 2022 owing to increased researchers' study in gene expression, technology advancement has contributed to the segment growth
  • The Phase II segment dominated the RNA therapy clinical trials market with a revenue share of 41.3% in 2022. The effectiveness of RNA therapy and the safety of RNA clinical trials will drive segment growth
  • In 2022, the rare diseases segment dominated the market and accounted for a revenue share of 21.8%. The key factors contributing to the growth include the growing burden of various types of rare diseases. Also, R&D expenditures made by market players drive the market growth
  • North America held the largest revenue share of 36.6% in 2022. The presence of well-established market players, the increasing burden of rare diseases, growing research activities on RNA, rising number of clinical trials drive the regional growth
  • Additionally, constant innovation and an emerging number of clinical studies and trials drive the market growth in the region. For instance, in December 2022, Moderna & Merck mentioned the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 a personalized mRNA cancer vaccine with KEYTRUDA combination. It is an mRNA cancer vaccine for melanoma stage III/IV patient treatment
  • Key players dominating the market include IQVIA; Laboratory Corporation of America Holdings; ICON Plc; Charles River Laboratories International, Inc.; PPD Inc.; Syneos Health; Medpace Holdings, Inc.; Novotech; PAREXEL International Corp.; and Veristat, LLC

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Modality Business Analysis

  • 4.1. RNA therapy clinical trials Market: Modality Movement Analysis
  • 4.2. RNA interference
    • 4.2.1. RNA interference Market, 2018 - 2030 (USD Million)
  • 4.3. Antisense therapy
    • 4.3.1. Antisense therapy Market, 2018 - 2030 (USD Million)
  • 4.4. Messenger RNA
    • 4.4.1. Messenger RNA Market, 2018 - 2030 (USD Million)
  • 4.5. Oligonucleotide, non-antisense, non-RNAi
    • 4.5.1. Oligonucleotide, non-antisense, non-RNAi Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trials Phase Business Analysis

  • 5.1. RNA therapy clinical trials Market: Clinical Trials Phase Movement Analysis
  • 5.2. Phase I
    • 5.2.1. Phase I Market, 2018 - 2030 (USD Million)
  • 5.3. Phase II
    • 5.3.1. Phase II Market, 2018 - 2030 (USD Million)
  • 5.4. Phase III
    • 5.4.1. Phase III Market, 2018 - 2030 (USD Million)
  • 5.5. Phase IV
    • 5.5.1. Phase IV Market, 2018 - 2030 (USD Million)

Chapter 6. Therapeutic Areas Business Analysis

  • 6.1. RNA therapy clinical trials Market: Therapeutic Areas Movement Analysis
  • 6.2. Rare Diseases
    • 6.2.1. Rare Diseases Market, 2018 - 2030 (USD Million)
  • 6.3. Anti-infective
    • 6.3.1. Anti-infective Market, 2018 - 2030 (USD Million)
  • 6.4. Anticancer
    • 6.4.1. Anticancer Market, 2018 - 2030 (USD Million)
  • 6.5. Neurological
    • 6.5.1. Neurological Market, 2018 - 2030 (USD Million)
  • 6.6. Alimentary/Metabolic
    • 6.6.1. Alimentary/Metabolic Market, 2018 - 2030 (USD Million)
  • 6.7. Musculoskeletal
    • 6.7.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 6.8. Cardiovascular Respiratory
    • 6.8.1. Cardiovascular Respiratory Market, 2018 - 2030 (USD Million)
  • 6.9. Sensory
    • 6.9.1. Sensor Market, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. RNA therapy clinical trials Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Framework
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. U.S. RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Framework
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Canada RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. UK RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Germany RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. France RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Italy RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Spain RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Sweden RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Norway RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.9. Denmark
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Denmark RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Japan RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. China RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. India RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Australia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. South Korea RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Thailand RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Brazil RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Mexico RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Argentina RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. South Africa RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Saudi Arabia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. UAE RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Kuwait RNA therapy clinical trials Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Merger& Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Product Launch
  • 8.3. Participant's overview
    • 8.3.1. IQVIA
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. ICON Plc
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Laboratory Corporation of America Holdings
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Charles River Laboratories International, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. PAREXEL International Corp.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Syneos Health
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Medpace Holdings, Inc.
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. PPD Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Novotech
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Veristat, LLC.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global RNA Therapy Clinical Trials Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 8 North America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 10 North America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 11 North America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 12 U.S. RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 13 U.S. RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 14 U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 15 Canada RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 16 Canada RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 17 Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 18 Europe RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 20 Europe RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 21 Europe RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 22 UK RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 23 UK RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 24 UK RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 25 Germany RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 26 Germany RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 27 Germany RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 28 France RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 29 France RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 30 France RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 31 Italy RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 32 Italy RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 33 Italy RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 34 Spain RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 35 Spain RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 36 Spain RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 37 Sweden RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 38 Sweden RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 39 Sweden RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 40 Norway RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 41 Norway RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 42 Norway RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 43 Denmark RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 44 Denmark RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 45 Denmark RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 50 Japan RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 51 Japan RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 52 Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 53 China RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 54 China RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 55 China RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 56 India RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 57 India RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 58 India RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 59 Australia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 60 Australia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 61 Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 62 South Korea RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 63 South Korea RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 64 South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 65 Thailand RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 66 Thailand RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 67 Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 68 Latin America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 70 Latin America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 71 Latin America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 72 Brazil RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 73 Brazil RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 74 Brazil RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 75 Mexico RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 76 Mexico RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 77 Mexico RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 78 Argentina RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 79 Argentina RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 80 Argentina RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 84 Middle East and Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 85 South Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 86 South Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 87 South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 91 UAE RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 92 UAE RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 93 UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 94 Kuwait RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 95 Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 96 Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RNA Therapy Clinical Trials Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2022)
  • Fig. 10 Strategy framework
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 RNA Therapy Clinical Trials Market: Modality movement analysis
  • Fig. 17 RNA Therapy Clinical Trials Market: Modality segment dashboard
  • Fig. 18 RNA Therapy Clinical Trials Market Modality outlook: Key takeaways
  • Fig. 19 RNA interference market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antisense therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Messenger RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Oligonucleotide, non-antisense, non-RNAi market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA Therapy Clinical Trials Market: Clinical Trials Phase movement analysis
  • Fig. 24 RNA Therapy Clinical Trials Market: Clinical Trials Phase segment dashboard
  • Fig. 25 RNA Therapy Clinical Trials Market: Clinical Trials Phase outlook: Key takeaways
  • Fig. 26 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 RNA Therapy Clinical Trials Market: Therapeutic Areas movement analysis
  • Fig. 31 RNA Therapy Clinical Trials Market: Therapeutic Areas segment dashboard
  • Fig. 32 RNA Therapy Clinical Trials Market: Therapeutic Areas outlook: Key takeaways
  • Fig. 33 Rare Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Anticancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Neurological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Alimentary/Metabolic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Cardiovascular Respiratory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sensory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Global RNA Therapy Clinical Trials market, 2018 - 2030 (USD Million)
  • Fig. 43 North America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 France RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 China RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 India RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 71 Heat map analysis
  • Fig. 72 Market differentiator